SCHEMBL8828641

SCHEMBL8828641

CN(C)C(=O)c1ccc(Cl)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.43
ALDH1A1 P00352 4/20 0.43
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40
TUBB2B Q9BVA1 1/20 0.40
TUBB1 Q9H4B7 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18149358 0.85 TUBB4A (0.38) CNR1ALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL18838583 0.83 CNR1 (0.43) CNR1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5425587 0.83 EGFR (0.47) CNR1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL18838559 0.83 ALDH1A1 (0.42) CNR1ALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL29663634 0.82 TUBB4A (0.43) CNR1ALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL3700292 0.82 TUBB4A (0.43) CNR1ALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL20077096 0.81 CNR1 (0.42) CNR1ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2073562 0.80 HDAC4 (0.38) CNR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20060890 0.79 POLB (0.47) CNR1ALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL18921602 0.79 TUBB4A (0.46) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) 2025-05-22 US disclosed
EP-4467537-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) 2024-11-27 EP disclosed
US-12037323-B2 Uracil derivatives as Mer-AXL inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
CN-117157288-A Pyridine derivative, preparation method and application thereof 成都苑东生物制药股份有限公司 2023-12-01 CN disclosed
US-20230339891-A1 URACIL DERIVATIVES AS MER-AXL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-10-26 US disclosed
WO-2023142641-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 成都苑东生物制药股份有限公司 2023-08-03 WO disclosed
WO-2023142641-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 成都苑东生物制药股份有限公司 2023-08-03 WO disclosed
EP-3373933-B1 BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2020-08-26 EP disclosed
EP-3373933-B1 BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2020-08-26 EP disclosed
US-20180305332-A1 Bispiperidinyl Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use MERCK SHARP & DOHME CORP. (US) 2018-10-25 US disclosed
EP-3373933-A1 BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE Merck Sharp & Dohme Corp. (US) 2018-09-19 EP disclosed
WO-2017083219-A1 BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-05-18 WO disclosed
WO-2017083219-A1 BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-05-18 WO disclosed
US-5688795-A URINARY TRACTS OBSTRUCTION SYNTEX (U.S.A.) INC. (US) 1997-11-18 US disclosed
EP-0711757-A1 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists F. Hoffmann-La Roche AG (CH) 1996-05-15 EP disclosed
EP-0388994-B1 Substituted pyridinesulfonamide compounds, herbicidal composition containing them, and method of preparing these compounds ISHIHARA SANGYO KAISHA (JP) 1994-10-05 EP disclosed
EP-0388994-A1 Substituted pyridinesulfonamide compounds, herbicidal composition containing them, and method of preparing these compounds ISHIHARA SANGYO KAISHA, LTD. (JP) 1990-09-26 EP disclosed
EP-0232067-A2 Substituted pyridinesulfonamide compounds, herbicidal composition containing them, and method of preparing these compounds ISHIHARA SANGYO KAISHA LTD. (JP) 1987-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037323-B2 Uracil derivatives as Mer-AXL inhibitors MERTK, DAPK1, AXL CNR1 3014/4885ALDH1A1 1072/4885TUBB4A 2646/4885
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF KDM1B, KDM1A, EZH2 CNR1 815/4885ALDH1A1 349/4885TUBB4A 3983/4885
US-20230339891-A1 URACIL DERIVATIVES AS MER-AXL INHIBITORS MERTK, DAPK1, AXL CNR1 3014/4885ALDH1A1 1072/4885TUBB4A 2646/4885
US-20180305332-A1 Bispiperidinyl Derivatives as Liver X Receptor Beta Agonists, Compositions, and Their Use NR1H2, NR1H3, NR1H4 CNR1 98/4885ALDH1A1 1775/4885TUBB4A 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.